Wells Fargo Says Outside Interest in Multiple Myeloma Space a Positive for Array Biopharma

Array Biopharma ARRY shares are up over 5 percent in Monday's afternoon session as the earlier Amgen AMGN, Onyx ONXX bid and the Celgene CELG MorphoSys partnership signals significant interest in the multiple myeloma space, according to Wells Fargo's Matthew Andrews. The analyst believes Array's ARRY-520 is an under-appreciated asset in this field. Andrews maintains an Outperform rating on shares of Array Biopharma.